2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.879

Change

-0.02 (-0.23)%

Market Cap

USD 1.14B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.10 (-0.20%)

USD 509.68B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.12%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.01 (-0.04%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.01 (+0.02%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.13 (-0.53%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.19 (+0.43%)

USD 101.50B
8R80:XETRA Amundi Index Solutions - Amund..

+0.12 (+0.08%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.07 (-0.13%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.98 (+0.74%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.01 (-0.05%)

USD 79.79B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.88% 30% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.88% 30% F 34% F
Trailing 12 Months  
Capital Gain -2.36% 13% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.36% 13% F 21% F
Trailing 5 Years  
Capital Gain 24.73% 47% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.73% 46% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 5.85% 55% F 55% F
Dividend Return 5.85% 55% F 53% F
Total Return N/A 2% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 22.31% 16% F 29% F
Risk Adjusted Return 26.21% 42% F 44% F
Market Capitalization 1.14B 81% B- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.